Novo Nordisk Cancels Bonuses for Danish Employees Amidst Performance Uncertainty.

Novo Nordisk, a Danish pharmaceutical company, has cancelled bonuses for its Danish employees in the first half of the year, affecting thousands of employees. The decision was made due to the company's performance. However, there may be room for bonuses in the second half of the year. The cancelled bonuses are part of the variable component of the employees' salaries.

Novo Nordisk, a Danish pharmaceutical giant, has decided to cancel bonuses for its Danish employees in the first half of 2025, affecting thousands of employees. This decision was taken due to the company's underperformance, particularly in the face of market pressures and increased competition. The cancellation of bonuses is part of the variable component of employees' salaries.

The company's decision comes amidst a period of significant market volatility and strategic challenges. Novo Nordisk has faced a series of governance failures, including the abrupt removal of CEO Lars Fruergaard Jørgensen in May 2025 without prior communication or transparency, which led to a 53% drop in the company's share price over 12 months [1].

Moreover, the company is grappling with over 2,190 lawsuits alleging serious side effects from its GLP-1 drugs, with potential liabilities estimated at $2–$5 billion [1]. The market overestimation of Novo's dominance has also collapsed as compounded alternatives and telehealth platforms captured 15% of the GLP-1 market in six months [1].

Adding to these challenges, Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, leading to a rapid expansion of its workforce. However, the company now faces cost pressure and heightened competition, with potential layoffs anticipated in the sales division [2].

The company's gross margin has been squeezed, reaching its lowest level in two and a half years in the second quarter. The stock market has wiped $490 billion off the company's market capitalisation since a peak last year when it was Europe's most valuable firm [2].

Despite these challenges, Novo Nordisk has indicated that there may be room for bonuses in the second half of the year, provided the company's performance improves. The company's ability to navigate its governance and legal crises will determine whether it can reclaim its position as an industry leader or become a cautionary tale for the sector.

References:
[1] https://www.ainvest.com/news/glp-1-market-volatility-novo-nordisk-strategic-risks-governance-legal-crossroads-2508/
[2] https://economictimes.indiatimes.com/news/international/business/riding-high-on-wegovy-novo-nordisk-doubled-its-workforce-now-layoffs-loom/articleshow/123425273.cms